A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers

被引:132
|
作者
Tang, XLC
Pikal, MJ
Taylor, LS [1 ]
机构
[1] Astra Zeneca R&D Molndal, Pharmaceut & Analyt R&D, Solid State Anal, S-43183 Molndal, Sweden
[2] Univ Connecticut, Sch Pharm, Storrs, CT 06296 USA
关键词
crystalline; amorphous; hydrogen bonding; vibrational spectroscopy;
D O I
10.1023/A:1015147729564
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To gain insight into the molecular structure of amorphous compounds by investigating hydrogen bonding patterns and strength in a series of structurally related compounds. Seven 1,4-dihydro- pyridine calcium channel blockers were evaluated. Methods. FT-Raman and FT-infrared spectra of the compounds in the crystalline and amorphous states were obtained. Results. For crystalline compounds, the position of the NH vibration varied considerably, indicating that the strength of hydrogen bonding differs between the different compounds in agreement with published single crystal X-ray data. For the amorphous phases, the NH vibration occurred at approximately the same position for all compounds, suggesting a uniform average hydrogen bonding strength. Somewhat surprisingly, for some compounds, the average hydrogen bond strength in the amorphous state was found to be greater than in the crystalline compound, although for others, it was weaker as anticipated. Hydrogen bonding patterns (acceptor group) varied between the crystalline compounds, but were remarkably consistent in the amorphous compounds; thus the acceptor group in the amorphous phase is not necessarily the same as in the crystalline counterpart. Conclusions. Hydrogen bond patterns and strength within a group of chemically related amorphous compounds were found to be very similar, but were different from those in the equivalent group of crystalline substances.
引用
收藏
页码:477 / 483
页数:7
相关论文
共 50 条
  • [21] THE INTERACTION OF DIHYDROPYRIDINE CALCIUM-CHANNEL BLOCKERS WITH CALMODULIN AND CALMODULIN INHIBITORS
    THAYER, SA
    FAIRHURST, AS
    MOLECULAR PHARMACOLOGY, 1983, 24 (01) : 6 - 9
  • [22] Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19
    Mendez, Sean R.
    Frank, Rachel C.
    Stevenson, Elizabeth K.
    Chung, Mabel
    Silverman, Michael G.
    CHEST, 2021, 160 (01) : 89 - 93
  • [23] Separation of five dihydropyridine calcium channel blockers by micellar electrokinetic chromatography
    Wang, J
    Chen, HF
    Zhao, LF
    CHINESE JOURNAL OF ANALYTICAL CHEMISTRY, 1999, 27 (01) : 82 - 84
  • [24] Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients
    Staessen, JA
    Birkenhäger, WH
    Fagard, RH
    EUROPEAN HEART JOURNAL, 2000, 21 (01) : 2 - 7
  • [25] Time course for blood pressure lowering of dihydropyridine calcium channel blockers
    Ghamami, Niousha
    Chiang, Sandy Hsiang Yu
    Dormuth, Colin
    Wright, James M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):
  • [26] Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
    Schneeweiss, S
    Soumerai, SB
    Maclure, M
    Dormuth, C
    Walker, AM
    Glynn, RJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (04) : 388 - 400
  • [27] SPECTROSCOPIC INVESTIGATION OF THE HYDROGEN BOND IN MERCAPTANS
    BULANIN, MO
    DENISOV, GS
    PUSHKINA, RA
    OPTIKA I SPEKTROSKOPIYA, 1959, 6 (06): : 754 - 759
  • [28] INVESTIGATION OF THE HYDROGEN BOND BY SPECTROSCOPIC METHODS
    MALYSHEV, VI
    USPEKHI FIZICHESKIKH NAUK, 1957, 63 (02): : 323 - 353
  • [29] Dihydropyridine calcium channel blockers may increase mortality in patients with heart failure
    Howlett, JG
    Johnstone, DE
    Cox, JL
    CIRCULATION, 2003, 108 (17) : 341 - 341
  • [30] Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma
    Pierce, Wesly A.
    Hederman, April D.
    Gordon, Catherine J.
    Ostrenga, Andrew R.
    Herrington, Betty
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (05) : 402 - 406